Shailender Bhatia, MD, on Pembrolizumab in Front-Line Treatment of Merkel Cell Carcinoma

Posted: Friday, December 4, 2020

Shailender Bhatia, MD, of the Fred Hutchinson Cancer Research Center, discusses the KEYNOTE-17 trial and its findings on the efficacy of pembrolizumab in front-line treatment of metastatic Merkel cell carcinoma, safety data on the drug, and the unmet needs of patients with this disease.